Early administration of <scp>COVID</scp>‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
Artur Belov(Center for Biologics Evaluation and Research), Peter Marks(Johns Hopkins University), Barbee Whitaker(Center for Biologics Evaluation and Research), Steven A. Anderson(United States Food and Drug Administration), Rickey E. Carter(Mayo Clinic in Florida), Michael S. Lauer, Deborah T. Hung(Massachusetts General Hospital), Carlos H. Villa(Center for Biologics Evaluation and Research), Mary J. Homer(Biomedical Advanced Research and Development Authority), Yin Huang(Center for Biologics Evaluation and Research), Nicole Verdun(Center for Biologics Evaluation and Research), Corey M. Hoffman(Biomedical Advanced Research and Development Authority), Michael J. Joyner(Mayo Clinic), Richard A. Forshee(Center for Biologics Evaluation and Research), Scott Wright(Mayo Clinic), Anne F. Eder(Center for Biologics Evaluation and Research)
Cited by 21
Related Papers
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram
|Nature Medicine|2018|1.3k
Definitions and guidelines for research on antibiotic persistence
|Nature Reviews Microbiology|2019|1.3k
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863
Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing
|New England Journal of Medicine|2020|801